Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 86

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 86
---
 lease liabilities, long-termOperating lease liabilities, long-term24,383 27,382 Total lease liabilities$31,774 $34,271 Supplemental cash flow information related to leases is as follows (dollars in thousands):Six Months Ended June 30,20252024Cash paid for operating leases$7,290 $8,138 Lease assets obtained for new operating leases900 3,525 

18

13. Segment Reporting

The Company operates in one operating segment and therefore has only one reportable segment. The Company derives revenue primarily from sales of its commercial products in the U.S.The Company's chief operating decision maker (CODM) is the chief executive officer. The Company manages the business activities on a consolidated basis. The CODM assesses performance of the Company, decides how to allocate resources based on net earnings (loss), which is reported in the condensed consolidated statement of earnings (loss) as net earnings (loss), and allocates resources on a consolidated basis. The CODM uses net earnings (loss) to decide whether to reinvest profits into the Company's current products or into other research and development initiatives for the Company's product candidates. Net earnings (loss) is also used to monitor budget versus actual results.The measure of the reportable segment assets is reported on the balance sheet as total assets. The following table shows the segment revenue, significant segment expenses and net earnings (dollars in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024(unaudited)(unaudited)Total revenues$165,453 $168,325 $315,277 $311,969 Less: Significant segment expenses:Cost of goods sold16,827 17,916 32,590 34,225 Selling44,398 39,094 87,012 78,108 Marketing20,732 19,710 41,396 40,263 General and administrative28,421 27,100 55,087 54,049 Research and development expensesExternal development program expenses:ONAPGO789 309 1,261 1,093 SPN-8202,199 6,604 6,962 13,342 SPN-8173,446 1,898 7,017 3,020 Qelbree2,224 3,880 6,637 5,931 Early-stage programs and